Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 13,596 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Recruiting Phase 3 Interventional

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT06663332
View directory record Official record
Conditions
Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Interventions
Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
6
States / cities
Atlanta, Georgia • Indianapolis, Indiana • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 5:35 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Childhood Alopecia Areata Study Using the 308-nm Excimer Laser

NCT01736007
View directory record Official record
Conditions
Alopecia Areata
Interventions
308-nm excimer laser to alopecia patch, Liquid light guide tip on laser
Device
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
6 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 24, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

NCT06013371
View directory record Official record
Conditions
Seborrheic Dermatitis, Papulopustular Rosacea
Interventions
PF-07038124, Placebo Ointment
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

NCT00770809
View directory record Official record
Conditions
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Lapatinib Ditosylate, Paclitaxel, Trastuzumab
Other · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
317
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Burbank, California + 222 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Not applicable Interventional

Effect of Rate (Slope) of Compression on the Incidence of Symptomatic ETD and MEB: a Phase III Prospective Study.

NCT04804098
View directory record Official record
Conditions
Ear Barotrauma, Middle Ear Disease, Ear Diseases, Pressure Injury, Eustachian Tube Dysfunction, Middle Ear; Injury, Middle Ear Barotrauma
Interventions
Compression Profile/Schedule: 15 minute Non-Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw), Compression Profile/Schedule: 15 minute Linear compression from start of the daily treatment until treatment pressure is reached (45 fsw)
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sleepy Hollow, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

NCT02832063
View directory record Official record
Conditions
Acne Vulgaris
Interventions
B244, Placebo
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 24, 2026, 5:35 PM EDT
Recruiting Not applicable Interventional

Perioperative Mindfulness Proposal

NCT04049214
View directory record Official record
Conditions
Breast Cancer, DCIS
Interventions
Meditation
Other
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 24, 2026, 5:35 PM EDT
Recruiting No phase listed Observational

A Real-World Registry of Chronic Wounds and Ulcers

NCT02280733
View directory record Official record
Conditions
Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis, Skin Ulcer, Leg Ulcer, Pyoderma, Peripheral Arterial Disease, Lymphedema, Surgical Complication, Venous Leg Ulcers (VLUs), Calciphylaxis, Sickle Cell Ulcer, Pressure Ulcer (PU), Diabetic Foot Ulcers (DFUs), Pressure Injury, Arterial Ulcers, Soft Tissue Radionecrosis (STRN), Traumatic Wounds, Chronic Ulcer
Interventions
Usual care
Other
Lead sponsor
U.S. Wound Registry
Other
Eligibility
Not listed
Enrollment
300,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2030
U.S. locations
1
States / cities
The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 24, 2026, 5:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

NCT00275795
View directory record Official record
Conditions
Food Sensitivities, Headache, Backache, Indigestion, Eczema, Acne, Hives and Itching of the Skin
Interventions
NAET Procedures
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
2 Years to 78 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2006 · Synced Oct 24, 2026, 5:35 PM EDT
Recruiting Early Phase 1 Interventional

Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)

NCT07319195
View directory record Official record
Conditions
Breast Cancer
Interventions
Intratumoral Mitazalimab, Intratumoral Nivolumab
Drug
Lead sponsor
Jennifer Zhang
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

NCT00521339
View directory record Official record
Conditions
Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 24, 2026, 5:35 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

NCT04140695
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Hoover, Alabama • Tempe, Arizona • Encino, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

NCT00091819
View directory record Official record
Conditions
Staphylococcal Skin Infection
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Efudex Treatment on Photoaged Skin

NCT00121511
View directory record Official record
Conditions
Photo-aging, Keratosis
Interventions
Efudex (5-fluorouracil)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 24, 2026, 5:35 PM EDT
Not listed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

NCT00012311
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, CMF regimen, carboplatin, cyclophosphamide, docetaxel, doxorubicin hydrochloride, etoposide, fluorouracil, ifosfamide, methotrexate, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years to 59 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 24, 2026, 5:35 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 24, 2026, 5:35 PM EDT
Active, not recruiting Phase 1 Interventional

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT05891171
View directory record Official record
Conditions
Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Interventions
AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 24, 2026, 5:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Stacked-Pulses Vs. Double-Pass Treatments of Facial Acne With a 1450 Nm Laser

NCT00306371
View directory record Official record
Conditions
Acne, Acne Scars
Interventions
1450nm diode laser
Device
Lead sponsor
Skincare Physicians of Chestnut Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2006 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers

NCT00536744
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
acoustical pulse energy (extracorporeal shockwave), Sham
Device · Other
Lead sponsor
SANUWAVE, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
View directory record Official record
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 24, 2026, 5:35 PM EDT
Active, not recruiting Phase 2 Interventional

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 24, 2026, 5:35 PM EDT
Completed No phase listed Observational

Efficacy of the Dabir Surfaces Micropressure Overlay for Decubitus Ulcer Prevention During Cardiac Surgery

NCT03884634
View directory record Official record
Conditions
Pressure Ulcer, Pressure Injury
Interventions
Dabir Micropressure Overlay
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
6,627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 24, 2026, 5:35 PM EDT
Completed Not applicable Interventional Results available

Low Level Laser Therapy for Radiation Induced Dermatitis in H & N Squamous Cell Carcinoma

NCT02384434
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
THOR Laser System for Low Level Laser Therapy (LLLT)
Device
Lead sponsor
Heath Skinner
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 24, 2026, 5:35 PM EDT